Chronic Hepatitis B Virus Infection

Infectious Diseases
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
1
PEG-IFNαPhase 2
Vir Biotechnology
Vir BiotechnologyCA - San Francisco
1 program
1
PEG-IFNαPhase 21 trial
Active Trials
NCT05970289Active Not RecruitingEst. Feb 2026
PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
Ropeginterferon alfa-2bN/A1 trial
Active Trials
NCT05494528UnknownEst. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vir BiotechnologyPEG-IFNα
PharmaEssentiaRopeginterferon alfa-2b

Clinical Trials (2)

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Start: Aug 2023Est. completion: Feb 2026
Phase 2Active Not Recruiting
NCT05494528PharmaEssentiaRopeginterferon alfa-2b

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Start: May 2021Est. completion: Dec 2024
N/AUnknown

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space